US EditionNovo halves Ozempic price to $499 a month for those paying cash
- Novo Nordisk and GoodRx announced a collaboration to offer Ozempic and Wegovy for $499 per month across 70,000 U.S. pharmacies starting in August 2025.
- This offer responds to political pressure, competitive market dynamics, and aims to improve access for uninsured or underinsured patients who face high out-of-pocket costs.
- Ozempic, a GLP-1 injectable for type 2 diabetes, and Wegovy, approved for obesity and liver disease treatment, both reduce major cardiovascular risks and have safety warnings about possible thyroid tumors.
- Dave Moore, Novo Nordisk's U.S. EVP, noted that while Ozempic has strong insurance coverage across the country, some individuals still pay for the medication themselves. He emphasized that even one person resorting to unauthorized and unsafe counterfeit versions is unacceptable.
- The price cut to $499, less than half the previous list price near $1,000, aims to keep patients using authentic FDA-approved medicines and followed a nearly 5% rise in Novo Nordisk shares.
Insights by Ground AI
Does this summary seem wrong?
76 Articles
76 Articles
U.S. patients can now get Ozempic for half price if they can pay cash
Novo Nordisk announced Monday that U.S. patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for US$499, for those who pay for medications on their own and don’t go through insurance.
·Canada
Read Full Article
Novo Nordisk halves Ozempic price in US
Ozempic is getting cheaper in the US. Novo Nordisk, the Danish pharma giant behind the GLP-1 diabetes and weight-loss drug, said it halved the monthly cost to $499 for patients without health insurance. Novo Nordisk has struggled in the US market this year: It was slow to introduce a direct-to-consumer sales platform, and competitors rolled out cheaper Ozempic copycats. Rival Eli Lilly has outpaced Novo in weight loss medication prescriptions. T…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources76
Leaning Left15Leaning Right5Center37Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 26%
C 65%
Factuality
To view factuality data please Upgrade to Premium
